<DOC>
	<DOCNO>NCT01450618</DOCNO>
	<brief_summary>This study retrospective observational study assess identifiable tolerability problem term comparative incidence among Human Immunodeficiency Virus ( HIV ) patient treat cART regimen include one four different protease inhibitor [ Atazanavir sulfate ( ATV ) , Darunavir ( DRV ) , Fosamprenavir ( FPV ) , Lopinavir ( LPV ) ] impact identifiable tolerability problem PI persistence , healthcare utilization , healthcare cost .</brief_summary>
	<brief_title>Comparative Tolerability Protease Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Initiated treatment Protease inhibitor ( PI ) base Combination antiretroviral therapy ( cART ) regimen Between 1864 year age index date At least 6 month continuous enrollment pharmacy benefit prior index date At least 6 month continuous enrollment pharmacy benefit follow index date At least 1 medical claim 6month followup period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>